Four years after executing a $310 million deal to sell Intellikine to Takeda, biotech entrepreneur Troy Wilson is back, springing out of stealth mode with a new company that has a full team, $60 million in financing, a cancer drug in-licensed from Johnson & Johnson and a plan to start mid-stage development with two Phase II studies launching later in the year. And he's done it while working out an OTC listing that puts him in a public market with an eye to moving up to one of the national exchanges.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
Takeda Pharmaceutical has a new U.S. biotech to add to its portfolio of drug developers. The pharma outfit announced this morning that it will buy out La Jolla, CA-based Intellikine and scoop up its
Infinity Pharmaceuticals, a 2005 Fierce 15 company, has scooped up the global development and commercialization rights to a portfolio of oral PI3K inhibitors developed by Intellikine, including one
La Jolla, CA-based startup Intellikine has quickly racked up 1,500 drug candidates that can influence the PI3 kinase pathway, an indication of the biotech company's intensity and a key reason it has
La Jolla, CA-based Intellikine has scooped up $51 million in venture fund commitments to support its work in one of the hottest fields in biomedical research. Novartis Bioventures led the financing